Kornimate/medical-research-clean huggingface dataset:
patient-centred smartphone ai for protecting vision in macular disease

Conditions: Age-Related Macular Degeneration

Summary: macular disease is the leading cause of blindness in the uk and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month \[required in 50% of visits\] - these patients are the 'frequent fliers' within ophthalmology units, visiting specialist hospital clinics on a monthly or bi-monthly basis. this project aims to create a home-monitoring algorithm that could in the future, enable the movement of 'monitoring' of chronic eye disease into the patients' homes: remotely identifying who does need an in-person appointment, and who can safely stay away from hospital.

the okko health application is a ce-marked medical software application that aims to monitor visual function, track symptoms and treatment, and improve patient knowledge about their condition. to monitor visual function, okko implements quick and engaging activities to assess visual function, contrast sensitivity, and hyperacuity. the aim of this is to develop the app to see if it is possible to detect changes in visual function in a timely manner. this would enable regular monitoring for disease progression and/or the response of visual function to treatments between clinical visits. home monitoring may reveal information that may support the early diagnosis of worsening conditions and may enable a greater understanding of disease progression or stabilisation. currently unpublished data collected using the okko health app highlights its acceptability when collecting visual acuity compared to gold standard techniques used in clinical practice. okko includes self-monitoring features which may result in an increased (disease) awareness including vision changes between clinic visits. okko offers symptom and treatment tracking functionality as well as education modules to increase literacy about the disease and treatment. these elements may improve the patient's self-efficacy, enable patient empowerment, and may increase the involvement of patients in their care and more thorough communication with ophthalmologists including shared decision-making processes. thus, these psychological and behavioural changes may alleviate the patient's burden.

Eligibility criteria:
inclusion criteria: * patients newly diagnosed with wet (neovascular) amd in at least on eye at the start of their anti-vgef treatment. * participants with wet amd in at least one eye undergoing anti-vgef therapy. * access to a device running a compatible software * apple device running ios 12 or later, * android devices running android 7.0 or later, * ability to read and understand english. * willing and able to provide informed consent. exclusion criteria: * vision worse than 6/60 or 1.0 logmar in both eyes. * significant cognitive impairment. * patients who do not have the manual dexterity to tap a screen.
comparative study of robot baba approach and chest breast approach for lateral neck dissection

Conditions: Thyroid Carcinoma; Robot Surgery; Endoscopic Surgery

Summary: objective to compare the advantages and disadvantages of robotic and conventional endoscopic thyroidectomy for thyroid cancer.

to compare the difference of operative time and complication between two operative methods in robot neck surgery and routine endoscopic surgery.

Eligibility criteria:
inclusion criteria: 1. papillary thyroid carcinoma with clinically suspected or confirmed lateral lymph node metastasis; 2. patient's concerns of neck scars and cosmetic requirement. the exclusion criteria were as follows: 1) tumor size \>4cm; 2) previous neck surgical history； 3）residual or recurrent tumors; 4) suspicious primary tumor or metastatic lymph node invasion of major vascular structures or recurrent laryngeal nerve. 5）metastatic lymph nodes occurred below the sternoclavicular joint.

Keywords: thyroid carcinoma robot surgery endoscopic surgery
a study of wx390 combined with toripalimab in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: the goal of this clinical trial is to evaluate the safety and preliminary efficacy of wx390 combined with toripalimab in patients with advanced solid tumors. the main questions it aims to answer are: * the maximum tolerated dose (mtd) and dose-limiting toxicity (dlt) of wx390; * safety and preliminary in combined therapy. participants will be treated with wx390 orally and toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.

this study will be an open-label, multicenter phase ib/iia clinical trial. after being informed about the study and potential risks, all patients giving written informed consent will undergo a 4-week screening period to determine eligibility for study entry. and then patents will be administered for 8 cycles treatment and 8 weeks safety follow up after the last dose of treatment. the efficacy and safety measures will be conducted and collected every cycle.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * histological or cytological confirmed advanced solid tumor, standard regimen failed or no standard regimen available * eastern cooperative oncology group (ecog) performance status of 0-1 * life expectancy of more than 3 months * at least one measurable lesion according to recist 1.1 * adequate organ function， * signed and dated informed consent exclusion criteria: * anti-cancer therapy within 30 days prior to the initiation of investigational treatment * major surgery within 30 days prior to the initiation of study treatment * received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment * toxicity from a previous anti-tumor treatment that does not return to grade 0 or 1 (except for alopecia) * patients who are suffering active interstitial lung disease * evidence of ongoing or active serious infection * history of human immunodeficiency virus (hiv) infection or active hepatitis b or c infection * inability to take medication orally * abuse of alcohol or drugs * people with cognitive and psychological abnormality or with low compliance * pregnant or lactating women
real-world data study to understand participant treatment outcomes for dupuytren's contracture

Conditions: Dupuytren's Contracture

Summary: this is an observational study, meaning participants will not receive any investigational treatment as part of this study. researchers will collect real-world data (rwd), based on usual care, to gain a more in-depth knowledge of the natural history and the treatment outcomes of dupuytren's contracture (dc) to evaluate the management of dc.

each participant of the study will have their data collected from the date of confirmed diagnosis of dc to the date of enrollment in the registry, post consent. data will be collected from the participants clinical records as well as from the participant directly. data will be collected through pulse infoframe's technology platform.

Eligibility criteria:
key inclusion criteria: * any adult with a confirmed clinical diagnosis of dc. * age 18 years (or age of majority in their jurisdiction) or older at time of enrollment. * willing to participate in the registry (including completion of epros) and complete the informed consent form. * having received dc treatment, either non-surgical or surgical, within 2 weeks before enrollment, at enrollment or any time after the date of enrollment or not having received dc treatment after confirmed diagnosis of dc. * able to participate in english based registry. key exclusion criteria: * not having a clinical diagnosis of dc. * age less than 18 years. * do not provide informed consent.

Keywords: real world data retrospective prospective registry
chidamide combined with exemestane (+/- goserelin) versus neoadjuvant chemotherapy in patients of stage ii-iii hr-positive/her2-negative breast cancer

Conditions: Breast Neoplasms

Summary: this is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage ii-iii hr +/her2- breast cancer patients with poor response to previous chemotherapy.


Eligibility criteria:
inclusion criteria: * female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following: 1. previous oophorectomy, or age ≥ 60 years; 2. age \< 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), e2 and fsh in postmenopausal levels; 3. premenopausal or perimenopausal female patients, must be willing to receive lhrh agonist therapy during the study; * all patients were confirmed by histopathology as estrogen receptor (er) positive (\> 10%), her2 receptor negative.follow the 2018 version of asco-cap her2-negative interpretation guideline criteria; * tumor stage ii-iii meeting the ajcc 8th version criteria, patients who have previously received 2 cycles of te regimen chemotherapy, with disease evaluation of sd or pd; * kps score ≥ 70 points; * organ function level must meet the following requirements: 1. bone marrow function anc ≥ 1.5 × 109/l (14 without growth factors); plt ≥ 100 × 109/l (7 without corrective treatment); hb ≥ 100 g/l (7) without corrective treatment; 2. liver and kidney function tbil ≤ 1.5 × uln; alt and ast ≤ 3 × uln; bun and cr ≤ 1.5 × uln and creatinine clearance ≥ 50 ml/min (cockcroft-gault formula); * able to undergo needle biopsy; * voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up exclusion criteria: * received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); * received any other anti-tumor therapy at the same time; * breast cancer, inflammatory breast cancer or occult breast cancer; * stage iv breast cancer; * breast cancer without histopathological diagnosis;
nutritional status of adult slovenes after the covid-19 epidemic

Conditions: Body Weight; Nutrition, Healthy; COVID-19 Pandemic

Summary: there is objective need to examine nutritional status (i.e., body mass index (bmi), body composition and dietary intake) of healthy adult slovenes after sars-cov-2 (covid-19) epidemic period. in the slovenian (pair of european union) adult population (with only 2 million inhabitants), we do not yet have representative data on the body composition of adult slovenes published in the scientific literature. in the study after the covid-19 pandemic period (4th wave) the investigators will use medically approved body analyzer (tanita 780 s ma, tokyo, japan) and standardized food frequency questionnaire (ffq). in addition, the investigators will measured body height of the participants with a portable altimeter (ade mz10042, germany). the research will include randomly recruited adults (participants) who will attend various free or/and paid publicly available seminars, congresses and fairs in slovenia, directly unrelated topics to physical activity or healthy eating (i.e., healthy and active lifestyle) thus obtaining a more realistic current population status.

in the study investigators will randomly but voluntarily enroll 700-1000 healthy adult participants within inclusion/exclusion criteria that are willing to participate in the study. investigators anticipate that for this number of adults (aged 18-80 years) will require approx. 5000 invited candidates (10-15 events), of both sexes. the methods to be used are body composition monitor and ffq. in addition to the assessment of bmi and body composition status, we will compare the proportion of obese subjects according to bmi and body fat percentage threshold criteria (by world health organization). for the dietary intake analysis the investigators will use the national a dietary software program, open platform for clinical nutrition, which is a web-based application developed by the jožef stefan institute in slovenia. the power of the sample was calculated on the basis of published body composition data on the adult population of the scientific monographs of the slovenian national institute of public health and data on the bmi of the scientific research on the dietary intake status of adults (si.menu). the participants included in the study will signed consent form for inclusion in the study and will not be remunerated financially for participation in the study.

Eligibility criteria:
inclusion criteria: * healthy adults * no bmi restriction * randomly invited exclusion criteria: * without currently competitive or top level athletes * without pregnant or lactating women and physically handicapped individuals * without active common chronic diseases (i.e., cancer, cvd, autoimmune diseases ect.) * without individuals with a pacemaker
reliability of the neurophysiology of pain questionnaire in the neck pain the cross-validation study

Conditions: Neck Pain; Pain Knowledge

Summary: the aim of this study is to study the validity and reliability of the modified pain neurophysiology questionnaire in patients with neck pain. after the ethics committee approval, women and men in turkey will be invited to the research via online advertisements (researchers' facebook, instagram, twitter accounts). the scale will be translated from english to turkish by two people who are fluent in turkish and english. a single turkish translation will be obtained with a common opinion from these two turkish translations. in ten trial phases, a preliminary assessment will be conducted with 15 participants to test the intelligibility of the scale. if there are participants who think that there is a problem with the intelligibility of the scale, they will be asked to explain which items they have problems understanding and why. after individuals are informed with the online voluntary consent form, participants will be asked to complete the modified pain neurophysiology questionnaire. modified pain neurophysiology scale questions and questions in the data collection form will be prepared through the google surveys application and will be sent to the participants via whatsapp, facebook, instagram and e-mail. participants will fill out the survey forms online. in order to evaluate the validity of the modified pain neurophysiology questionnaire, the pain subscale of the sf-36 scale, which has been validated in turkish, will be used (mchorney, ware, lu, and sherbourne, 1994), (kocyigit et al., 1999). scales after 15 days to assess test-retest reliability will be repeated.


Eligibility criteria:
inclusion criteria: * be between the ages of 18-65 * having neck pain complaints for the last 3 months * adult individuals who agreed to participate in the study. their mother tongue is turkish. exclusion criteria: * not answering all the questions

Keywords: neck pain neurophysiology of pain pain knowledge pain education
evaluation if physostigmine reduces symptoms in patients who has developed a delirium in intensive care after a surgery

Conditions: Suspected Delirium After Elective or Emergency Heart Surgery; CAM-ICU Diagnosed Delirium

Summary: evaluation if physostigmine reduces symptoms in patients who has developed a delirium in intensive care after a surgery


Eligibility criteria:
inclusion criteria: * patients of both genders aged \> 18 years, \< 85 years of icu c1 after elective or emergency heart surgery with or without extracorporeal circulation (heart-lung machine and/or extracorporeal membrane oxygenation), with suspected delirium. (may be suspected if a patient does not show adequate improvement of vigilance 24 h after adequate reduction or stop of sedative medicine) * patients (\>18a, \<85a) with cam-icu diagnosed delirium * patients of legal capacity and patients with appointed representative exclusion criteria: * asthma * hypersensitivity against physostigmine salicylate, sodium metabisulfite, nitrogen * gangrene mechanical obstipation * mechanical urinary retention * dystrophia myotonica * depolarization block after depolarising muscle relaxants * intoxications with "irreversibly acting" cholinesterase inhibitors * closed head trauma * obstructions at gastro-intestinal tract and at urinary tract * neurological diseases * left ventricular ejection fraction \< 40% * simultaneous participation in other clinical trials or participation ind other clinical trials in the last 30 days * untreated coronary heart disease * wish to have children, pregnancy or nursing * patients with addictive disorder in medical history

Keywords: delirium cam-icu
classification and characterization of patients treated with efalizumab for plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the main objectives of the project are: * to classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in psoriasis area and severity index (pasi), psoriasis disability index 8pdi) and dermatology life quality index 8 dlqi) * to characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

this is an investigator initiated,prospective, longitudinal, observation study. before starting treatment with efalizumab we will record factors such as demographic data, type of psoriasis, previous treatment, other diseases etc. we will follow the patients and classify them as responders and non-responders. we hope to find 4-5 factors which we can use later to predict response of this drug.

Eligibility criteria:
inclusion criteria: * moderate to severe plaque psoriasis for more than six months * eligible for efalizumab treatment according to current norwegian guidelines exclusion criteria: * pregnant or breast-feeding patients * patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection. * patients suffering from hiv, hepatitis b or c, active tuberculosis, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year. * patients with history of cancer in the preceding 5 years, including lymphoproliferative disorders. patients with history of fully resolved basal cell or squamous cell skin cancer may be enrolled. * patients with impaired renal or hepatic function.

Keywords: drug therapy efalizumab
genetic alteration after systemic treatment in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to investigate effects of systemic treatments on genomic profiles in patients with breast cancer and to compare genomic profiling between premenopausal and postmenopausal women by systemic treatments in breast cancer.

prospective single arm trial using three patients' cohorts. one-hundred patients for each cohort and a total of 300 patients (600 biopsy samples) will be entered to this trial. the hypothesis is that genomic alterations measured by cancerscan and cfdna, whole exome sequencing (wes), whole transcriptome sequencing (wts), facs(fluorescence-activated cell sorting), cytokine and immunologic signature analysis would be different between pre- and post-menopausal women and would be predictive biomarkers for each cohort according to pre- and post-menopausal status. three groups of patients will be recruited: 1. the patients who receive neoadjuvant systemic treatments: 2. the patients who have distant metastatic sites at first and recur from surgery: 3. the patients who are going to receive first-line chemotherapy

Eligibility criteria:
inclusion criteria: 1. patients older than 20 years 2. patients with histologically confirmed breast cancer at three disease status * patients who are going to receive neoadjuvant chemotherapy with feasible biopsy site. * patients who recur from curative surgery and have distant metastasis with feasible biopsy site. ; patients must have received adjuvant chemotherapy after curative surgery. * patients who are going to first-line palliative chemotherapy with feasible biopsy site. 3. patients with ps ecog 0 - 2 4. patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations. 5. written informed consent form 6. patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to study as defined below: * haemoglobin ≥9.0 g/l (transfusion allowed) * white blood cells (wbc) \> 3 x 109/l * total bilirubin ≤ 1.5 x institutional upper limit of normal (uln) * ast (sgot)/alt (sgpt) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x uln exclusion criteria: 1. concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical condition that would interfere with the subject's safety. 2. double primary cancer (except for any cancer in remission for \> 5 years, cervix cancer in situ, basal cell cancer in situ, any in situ cancers that are resected)
3d flair versus coronal t2-wi mri in detecting optic neuritis (flacon)

Conditions: Optic Neuritis; Multiple Sclerosis; Encephalopathy

Summary: 3d flair, 3d t1 fat sat, coronal t2 and coronal t1 dixon sequences were usually used to assess visual deficits in mri. optic nerve examination is preferably performed using a coronal t2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain examination is preferably performed using a 3d flair sequence to highlight signs of spatial dissemination and lesions suggestive of multiple slerosis (ms). recently, a study based on a small number of patients showed the interest of 3d flair in the detection of the hypersignal of the optic nerve.the objective of this retrospective study is to determine whether a single 3d flair sequence allows simultaneous exploration of the optic nerve and the brain for the positive diagnosis of optic neuropathy and/or ms.


Eligibility criteria:
inclusion criteria: * age \> 18 years * decrease in visual acuity explored in mri between january 2018 and january 2020 exclusion criteria: * past history of episode of optic neuritis